Evidence map›Paper›PMID 32678923›Full record

ArticleJournal of orthopaedic research : official publication of the Orthopaedic Research Society2020

Abnormal epiphyseal development in a feline model of Sandhoff disease.

Margaret A McNulty, Patricia B Prevatt, Elizabeth R Nussbaum, Ashley N Randle, Aime K Johnson, Judith A Hudson, Heather L Gray-Edwards, Miguel Sena-Esteves, Douglas R Martin, Cathy S Carlson

Abstract read
In one paragraph

Article in Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Gene Therapy of Sphingolipid Metabolic Disorders.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Margaret A McNultyDepartment of Anatomy, Cell Biology, and Physiology, Indiana University School of Medicine, Indianapolis, Indiana.ORCID 0000-0001-6638-253X
Patricia B PrevattDepartment of Anatomy, Physiology, and Pharmacology, Auburn University College of Veterinary Medicine, Auburn, Alabama.
Elizabeth R NussbaumDepartment of Veterinary Clinical Sciences, University of Minnesota College of Veterinary Medicine, St Paul, Minnesota.
Ashley N RandleDepartment of Clinical Sciences, Auburn University College of Veterinary Medicine, Auburn, Alabama.
Aime K JohnsonScott-Ritchey Research Center, Auburn University College of Veterinary Medicine, Auburn, Alabama.
Judith A HudsonDepartment of Clinical Sciences, Auburn University College of Veterinary Medicine, Auburn, Alabama.
Heather L Gray-EdwardsScott-Ritchey Research Center, Auburn University College of Veterinary Medicine, Auburn, Alabama.
Miguel Sena-EstevesDepartment of Neurology and Gene Therapy Center, University of Massachusetts Medical School, Worchester, Massachusetts.
Douglas R MartinDepartment of Anatomy, Physiology, and Pharmacology, Auburn University College of Veterinary Medicine, Auburn, Alabama.
Cathy S CarlsonDepartment of Veterinary Clinical Sciences, University of Minnesota College of Veterinary Medicine, St Paul, Minnesota.

Funding

AAV-mediated gene therapy for GM2-gangliodosesU01NS064096 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ESTEVES, MIGUEL S · 2009 to 2012
$3.5M
NIH HHS NS064096NINDS NIH HHS U01 NS064096
6 · The paper itself

Abstract

Sandhoff disease (SD) is caused by decreased function of the enzyme β-N-acetylhexosaminidase, resulting in accumulation of GM2 ganglioside in tissues. Neural tissue is primarily affected and individuals with the infantile form of the disease generally do not survive beyond 4 years of age. Current treatments address neurometabolic deficits to improve lifespan, however, this extended lifespan allows clinical disease to become manifest in other tissues, including the musculoskeletal system. The impact of SD on bone and joint tissues has yet to be fully determined. In a feline model of infantile SD, animals were treated by intracranial injection of adeno-associated virus vectors to supply the central nervous system with corrective levels of hexosaminidase, resulting in a twofold to threefold increase in lifespan. As treated animals aged, signs of musculoskeletal disease were identified. The present study characterized bone and joint lesions from affected cats using micro-computed tomography and histology. All affected cats had similar lesions, whether or not they were treated. SD cats displayed a significant reduction in metaphyseal trabecular bone and markedly abnormal size and shape of epiphyses. Abnormalities increased in severity with age and appear to be due to alteration in the function of chondrocytes within epiphyseal cartilage, particularly the articular-epiphyseal complex. Older cats developed secondary osteoarthritic changes. The changes identified are similar to those seen in humans with mucopolysaccharidoses. Statement of clinical significance: the lesions identified will have significant implications on the quality of life of individuals whose lifespans are extended due to treatments for the primary neurological effects of SD.

Indexed as

AnimalsCatsDisease Models, AnimalGenetic TherapyGrowth PlateSandhoff DiseaseX-Ray Microtomographyanimal modelsbone developmentchondrocytesgangliosidosisgrowth plate

Identifiers

PMID32678923
PMCPMC8241401

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.